Lung Cancer

Nivolumab has now been shown to have an overall survival benefit versus docetaxel in both nonsquamous and squamous non–small cell lung cancer.

New England Journal of Medicine Publishes Study Co-Led by Hollings Cancer Center Researcher Showing Potential of New Genomic Test In Lung Screening.

The definition of liquid biopsy has expanded to include the collection of cell-free DNA (cfDNA), along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of patients with cancer.

Eric Haura, MD, senior member, Moffitt Cancer Center, discusses new approaches to identifying bypass signaling mechanisms and biomarkers in lung cancer.

Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center explains the importance of minimizing the long-term consequences of radiation.

The recent approval of nivolumab in the non–small cell lung cancer setting marks a unique shift in the treatment landscape of this malignancy, one that harnesses the patient's own immune system to target the tumors. However, there are challenges in using these agents.

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET and if it is still a relevant target in lung cancer.

Alice Tsang Shaw, MD, PhD, thoracic oncologist, Massachusetts General Hospital Cancer Center, discusses overcoming resistance to targeted therapy in lung cancer.

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discuses the impact of the FDA's approval of nivolumab's for the treatment of squamous non-small cell lung cancer.

James Welsh, MD, associate professor of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses a study that examined the regulation of PD-L1 and how it may open up more treatment options for patients with non-small cell lung cancer.

The FDA has granted a breakthrough therapy designation to crizotinib as a potential treatment for patients with ROS1-positive non–small cell lung cancer.

Evan W. Alley, MD, PhD, discusses the results from the phase Ib KEYNOTE-028 trial on a cohort of patients with malignant pleural mesothelioma.

Pembrolizumab had an overall response rate (ORR) of 45.2% among a cohort of patients with PD-L1-positive non–small cell lung cancer (NSCLC) and an ORR of nearly 20% in the full population in the phase I KEYNOTE-001 trial.

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.

Treatment with AZD9291 at 80 mg per day elicited a response in 66% of patients with EGFR T790M-positive non–small cell lung cancer.

Nivolumab (Opdivo) improved survival versus docetaxel in patients with pretreated nonsquamous non–small cell lung cancer in the phase III CheckMate-057 trial.

Brigatinib, an investigational ALK tyrosine kinase inhibitor, demonstrated significant intracranial antitumor activity in patients with ALK-positive non–small cell lung cancer and brain metastases.

Tracey L. Evans, MD, associate professor of clinical medicine, University of Pennsylvania Health System, discusses treatment of poor performance status (PS) and elderly patients with lung cancer.

Thomas Lynch, who is director of the Yale Cancer Center and physician-in-chief at the Smilow Cancer Hospital at Yale-New Haven, recently sat down with OncLive and discussed key strategies and trends in the management of lung cancer.

James P. Stevenson, MD, discusses optimization of drug and patient selection for maintenance therapies in NSCLC, and how it will continue to be a research focus in today's environment of value-based care.

Eligibility criteria set by the Centers for Medicare & Medicaid Services for coverage of low-dose computed tomography for individuals deemed at high risk for lung cancer may actually exclude many potential lung cancer patients who would benefit from screening.

Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses expanding the number of molecular subsets in non-small cell lung cancer (NSCLC).

Increasing the minimum age of legal access (MLA) to tobacco products will prevent or delay initiation of tobacco use by adolescents and young adults, particularly those ages 15 to 17, and improve the health of Americans across the lifespan.

Prior cancer history should not exclude patients with advanced lung cancer from participating in clinical trials because it does not impact clinical outcomes.

OncLive sat down with Edward Kim, MD, to learn more about the impact of recent advances in NSCLC and what the future treatment paradigm might look like.

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.